Pancreatic Cancer Research

ResearcherJuntendo UniversityActive in the last 2 years

Akio Saiura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5600-2847; OpenAlex author ID A5075220614, A5152800315. Sources: OpenAlex.

Their work

Papers
38 (first author 3, last author 10)
Trials
0
Grants
0
Labs led
2
Collaborators
71
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 3 papers · 2022: 6 papers · 2023: 7 papers · 2024: 5 papers · 2025: 3 papers · 2026: 4 papers

Papers 38

  1. Surgical strategy using arterial shaving technique for superior mesenteric artery involvement in pancreatic cancer. Last author DOI 10.1016/j.gassur.2026.102338↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. DNA hypermethylation of nonspecific cytotoxic cell receptor protein 1 and poor prognosis of pancreatic cancer. Co-author DOI 10.3892/ol.2026.15534↗
  4. Pancreatic Cancer after Living-Donor Liver Transplantation: A Case Report of Long-Term Recurrence-Free Survival after Pancreaticoduodenectomy Followed by Adjuv… Last author DOI 10.70352/scrj.cr.26-0464↗
  5. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  6. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  7. Differentiation of Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma by Diffusion-Weighted Magnetic Resonance Imaging With Weighted Diffusion Subtr… Co-author DOI 10.7759/cureus.81438↗
  8. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  9. Analyzing the high frequency of false-positive carcinoembryonic antigen elevations in postoperative pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00423-024-03577-5↗
  10. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Co-author DOI 10.1093/bjs/znad417↗
  11. Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Survival Following Curative Resection. Co-author DOI 10.1245/s10434-023-14408-0↗
  12. Survival Analysis of Conversion Surgery in Borderline Resectable and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma Addressing Selection and Im… Last author DOI 10.1245/s10434-024-16203-x↗
  13. Outcomes of pancreatic cancer with liver oligometastasis. Co-author DOI 10.1002/jhbp.1184↗
  14. Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort. First author DOI 10.1007/s00535-023-02033-3↗
  15. Radical antegrade modular pancreatosplenectomy enhances local control of the disease in patients with left-sided pancreatic cancer. Last author DOI 10.1016/j.hpb.2022.08.004↗
  16. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Co-author DOI 10.1016/j.hpb.2022.09.012↗
  17. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era. Co-author DOI 10.1016/j.hpb.2023.05.366↗
  18. Serum DUPAN-2 could be an Alternative Biological Marker for CA19-9 Nonsecretors with Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005395↗
  19. Impact of sarcopenia on S1 adjuvant chemotherapy and prognosis in pancreatic cancer patients. Co-author DOI 10.5582/bst.2023.01209↗
  20. Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreato… Co-author DOI 10.1007/s00268-022-06457-5↗
  21. Survival comparison of invasive intraductal papillary mucinous neoplasm versus pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2022.01.013↗
  22. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. Co-author DOI 10.1245/s10434-021-10560-7↗
  23. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Ret… Co-author DOI 10.1245/s10434-022-11471-x↗
  24. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… Co-author DOI 10.1245/s10434-022-11503-6↗
  25. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcit… Co-author DOI 10.1245/s10434-022-11621-1↗
  26. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Co-author DOI 10.1016/j.pan.2020.11.026↗
  27. Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. Co-author DOI 10.1093/bjs/znaa111↗
  28. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … Co-author DOI 10.1097/sla.0000000000003487↗
  29. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. Last author DOI 10.1002/bjs5.50268↗
  30. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Last author DOI 10.1007/s00423-019-01846-2↗
  31. Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer. Last author DOI 10.1007/s11605-019-04203-2↗
  32. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor locatio… Co-author DOI 10.1016/j.pan.2020.07.004↗
  33. Commentary: Complex venous resection and reconstruction for locally advanced pancreatic cancer: Our approach. Last author DOI 10.1016/j.surg.2020.08.003↗
  34. Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety. First author DOI 10.1007/s11605-018-3995-3↗
  35. Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0222155↗
  36. Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer. Co-author DOI 10.3390/jcm7070172↗
  37. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a sin… Co-author DOI 10.1093/jjco/hyu159↗
  38. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer. First author DOI 10.1007/s00268-012-1622-0↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yu Takahashi · 20 shared papers, 2019–2024 · strength 2.99
  2. Yosuke Inoue · 21 shared papers, 2018–2024 · strength 2.99
  3. Hiromichi Ito · 18 shared papers, 2019–2024 · strength 2.71
  4. Atsushi Oba · 16 shared papers, 2019–2024 · strength 2.41
  5. Yoshihiro Ono · 17 shared papers, 2012–2024 · strength 2.33
  6. Ryuji Yoshioka · 7 shared papers, 2012–2026 · strength 1.43
  7. Masato Ozaka · 8 shared papers, 2015–2024 · strength 1.11
  8. Takashi Sasaki · 7 shared papers, 2020–2024 · strength 1.05
  9. Naoki Sasahira · 7 shared papers, 2020–2024 · strength 1.05
  10. Yoshinori Takeda · 4 shared papers, 2022–2026 · strength 1.02
  11. Yuta Ushida · 4 shared papers, 2021–2022 · strength 0.57
  12. Haruka Tanaka · 2 shared papers, 2024–2026 · strength 0.55
  13. Hiroyuki Isayama · 2 shared papers, 2024–2025 · strength 0.45
  14. Tsuyoshi Takeda · 3 shared papers, 2020–2023 · strength 0.44
  15. Akio Saiura · 2 shared papers, 2020–2026 · strength 0.41
  16. Yoshihiro Ono · 2 shared papers, 2023–2024 · strength 0.39
  17. Takafumi Mie · 3 shared papers, 2020–2022 · strength 0.38
  18. Manabu Takamatsu · 2 shared papers, 2022–2024 · strength 0.36
  19. Masato Matsuyama · 3 shared papers, 2015–2023 · strength 0.34
  20. Genki Watanabe · 2 shared papers, 2022–2023 · strength 0.33
  21. Yu Norimatsu · 1 shared paper, 2026 · strength 0.33
  22. Kojiro Omiya · 2 shared papers, 2023–2024 · strength 0.33
  23. Yuki I. Kawamura · 1 shared paper, 2026 · strength 0.30
  24. Mai Nakamura · 1 shared paper, 2026 · strength 0.30
  25. Naoki Matsuya · 1 shared paper, 2026 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.